688062.SHG Mabwell (Shanghai) Bioscience Co. Ltd. A

Healthcare Biotechnology Shanghai Stock Exchange
24.07 CNY
Close of Nov 4, 2026
19.77 47.80
Market cap
CNY 9.62B
P/E
-
P/B
10.44x
ROE
-119.5%
Dividend yield
0.81%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688062.SHG undervalued?

Graham number

The Graham number of Mabwell (Shanghai) Bioscience Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mabwell (Shanghai) Bioscience Co. Ltd. A fundamental analysis

No fundamental analysis for Mabwell (Shanghai) Bioscience Co. Ltd. A yet.

Mabwell (Shanghai) Bioscience Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mabwell (Shanghai) Bioscience Co. Ltd. A

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injecti…

Full company profile